Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. Results: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy has some adverse events.Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients

Hamid Attarian

Hamid Rezvani

Mojtaba Ghadyani

Shirin Haghighi

Directory of Open Access Journals

673Vol. 9    |    No. 4    |    Fall 2012    |UROLOGY  JOURNALEfficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer Hamid Rezvani, Shirin Haghighi, Mojtaba Ghadyani, Hamid AttarianPurpose:Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. Results: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events.Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeu-tic outcome in this group of patients. Keywords: prostatic neoplasms, treatment failure, antineoplastic agents, drug resistance Corresponding Author:Hamid Attarian, MDTaleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Tel: +98 21 2243 2560Fax: +98 21 2243 2570                                                             E-mail: hattarian@hotmail.comReceived March 2012Accepted March 2012Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranUROLOGICAL ONCOLOGY674 |INTRODUCTIONP -cer in both genders and the second most common cancer in men. An estimated 900 000 men world-wide were diagnosed with PCa in 2008, accounting for al-most one in seven (14%) cancers diagnosed in men (7% of the total in men and women).(1) There have been large increases in the incidence of PCa in many countries world-wide, coupled with little change or small declines in mortal-ity.(2) report from Tehran population-based cancer registry showed that PCa is the second most common cancer in Tehran only after gastric cancer with age-standardized rate (ASR) of 15.6.(3) Based on another report of cancer registry in 5 prov-inces in Iran, during 5-year follow-up from 1996 to 2000, the ASR of PCa was 5.1 per 100 000 people in a year.(4) The ASR of PCa in Iran shows a slow rise with increasing age.  Hormone therapy in patients with metastatic PCa usually over the time, most patients will develop progressive disease, which is resistant to hormone therapy. The appropriate therapy for patients with hormone-resistant (5,6) The combination with prednisolone was 19.2 months, compared prednisolone.(7) Several studies have showed that thalido-factor.(8,9) -cations with different mechanism of action in treatment of hormone-resistant PCa.        MATERIALS AND METHODSAll recruited patients (16) had advanced metastatic PCa and were symptomatic despite orchiectomy or treatment with GnRH agonists alone or in combination with antiandrogens. as follows: 1. Constant bone pain;2. 50% increase in serial PSA level more than nadir in as-sociation with 2 ng/cc increase in PSA in patients who had 50% decrease in serial PSA level after initial therapy, which occurred despite suppressed level of testosterone (50 ng/dL);3. 25% increase of nadir level in patients who did not have 50% decrease in serial PSA level after initial therapy, which occurred despite suppressed levels of testosterone (50 ng/dL);4. Appearance of new lesions in bone scan or increased dis-tant metastasis in imaging studies. The inclusion criteria were age > 18 years, Eastern Coop-erative Oncology Group performance status (PS) = 0 to 1, 3, platelet count at ULN, alkaline phosphatase < 2.5 ULN, serum creatinine < 1.5 mg/dL, or creatinine clearance at least 40 cc/mL. Patients should have no history of myocardial infarction within recent 6 months, no evidence of congestive heart failure or unstable angina, no history of previous chemotherapy for metastatic with history of neuropathy, thrombophlebitis, brain metasta-the study.   A written informed consent was obtained from all the pa-tients. The primary objective was to observe if there is any -re-measurement of PSA level two weeks later.(7) Secondary objectives were time to progression of the disease, overall survival rate, and adverse effects. -water, NJ) 75 mg/m2day, which was repeated every 3 weeks. They also received thalidomide (Celgene Corporation; Warren, NJ) 50 mg/day and prednisolone 10 mg/day orally. Aspirin 80 mg/day was --essary. In patients who did not undergo bilateral orchiectomy, medical castration with GnRH analogs was continued.Patients were evaluated every 3 weeks before undergoing chemotherapy and their symptoms, signs, and PSA levels Urological Oncology675Vol. 9    |    No. 4    |    Fall 2012    |UROLOGY  JOURNALwere documented. All the patients had basal serum PSA lev-abdomen, and pelvic. These evaluations were repeated every 3 cycles. All responses were evaluated based on PSAWG criteria and response evaluation criteria in solid tumor (RE-CIST). The pain was evaluated by visual analogue scaling (VAS) from 0 to 10; as mild (0 to 2), moderate (3 to 5), se-vere (6 to 8), and very severe (9 to 10). Adverse effects were evaluated based on National Cancer Institute (NCI) common (10,11)  -developed grade IV febrile neutropenia after receiving peg--ceiving thalidomide or if grade II peripheral neuropathy was developed, thalidomide was discontinued. In patients that Statistical AnalysisThe percentage of difference in PSA level from baseline to nadir level was calculated and reported as waterfall plot (Fig-ure 1).(12)was reported.--lesion at baseline.  Considering secondary objectives, progression-free survival (PFS) was calculated at the recruitment time until appear-follow-up. Progressive disease was considered if each of the following items occurred:1. 25% increase in the size of all soft tissue masses or pres-entation of new lesions. The partial response based on bone scan was considered when 2 or more new lesions disap-2. Need to do radiotherapy;3. Two times increase in PSA level more than 50% of nadir in patients who had PSA response and more than 25% in-crease from nadir or baseline PSA (either that was less), and also increase in absolute level of PSA at least 5 ng/mL that is -sponsive for PSA.   In patients that PSA level decreased, but did not reach the -nadir that should increase at least 5 ngr/cc.The time of overall survival rate was determined from re-Figure 1. The percentage of difference in prostate-specific anti-gen level from baseline.Taxotere  in PCa   |  Rezvani et al676 |cruitment time to death date (for any cause). Patients who remained in the study or were alive at the time of analysis were followed-up on the last day. The probability of PFS was estimated by Kaplan-Meier method (Figure 2).RESULTSMean age of the patients was 72.7 ± 5.39 years (range, 65 to 85 years). Mean Gleason score of the patients was 8 ± 0.71 (range, 6 to 8). The performance status was zero in 15 patients and 1 in one patient. Twelve patients had undergone prostatectomy and 4 had received radiotherapy. Fourteen patients only had bone metastasis and 3 only had soft tis-sue metastasis, while 2 patients had both soft tissue and bone metastases.Mean serum level of PSA before treatment was 221.4 ± 165.3 ng/mL. Percentage of difference in PSA level from baseline to nadir was reported as waterfall plot. Ninety-four percent of 3 months of therapy.(100%) adverse events were noted in 16 study subjects. Ad-verse effects were grade II fatigue in 10 (62%) patients, grade II weight loss in 3 (18%), peripheral neuropathy in 1 (6.2%), and grade I neutropenia in 2 (12%) patients. The PFS was 15 months and mean overall survival rate was 23 months. DISCUSSION(6,13)resistant PCa. Prostate tumors should have angiogenic phenotype for pro-gression to aggressive form.(14,15) Without angiogenesis, pri-mary tumors of the prostate will remain indolent and their agent that inhibits angiogenesis, induces apoptosis in vitro, and reduces higher levels of angiogenic factors, such as VEGF and BFGF in patients with PCa.(9)40% in 27% of patients, and clinical symptoms disappeared in most of them.(16) In another phase II study on 75 patients with hormone-resistant PCa, patients were divided into two respectively (P = .32). After 18 months, rate of overall sur-group. In a randomized phase II trial on patients with hormone--lidomide or placebo in two groups of patients. Patients who PSA reduction (53% versus 37%) and also higher mean pro-gression-free survival (5.9 versus 3.7 months; P = .32). The months versus 15 months in other group.(7) The combination therapy was tolerated by most of the patients, but thrombo-embolic events occurred in 28% of patients who did not re-In our study, in 94% of patients who received the combina-tion therapy, PSA decreased more than 50%. Mean time to progression was 15 months and mean survival rate was 23 months. The response rate of PSA and mean time to progres-sion of disease were considerably raised. In a phase II clini-and prednisone were used in patients with hormone-resistant Urological OncologyFigure 2. Kaplan-Meier plots of prostate-specific antigen non-progressive survival.677Vol. 9    |    No. 4    |    Fall 2012    |UROLOGY  JOURNALPCa, high response rate of 50% reduction in PSA was 88% and PFS was 18.2 months.(17)CONCLUSIONprednisolone regimen was an effective combination therapy -verse effects.CONFLICT OF INTERESTNone declared.         Taxotere  in PCa   |  Rezvani et alREFERENCES1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.2. Boyle P, Levin B. World Cancer Report 2008: IARC Press, International Agency for Research on Cancer; 2008.3. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med. 2009;12:15-23.4. Sadjadi A, Nooraie M, Ghorbani A, et al. The incidence of prostate cancer in Iran: results of a population-based can-cer registry. Arch Iran Med. 2007;10:481-5.5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus pred-nisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.6. Bissery MC, Vrignaud P, Bayssas M. Preclinical in vivo activ-ity of docetaxel containing combinations. Proc Am Soc Clin Oncol. 1995;489.7. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-5.8. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independ-ent prostate cancer. J Clin Oncol. 2004;22:2532-9.9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-5.10. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-7.11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. Eu-ropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.12. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-59.13. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and pred-nisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.14. Jones A, Fujiyama C. Angiogenesis in urological malig-nancy: prognostic indicator and therapeutic target. BJU Int. 1999;83:535-55; quiz 55-6.15. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and thera-peutic targets in prostate cancer. Scand J Urol Nephrol. 2001;35:437-52.16. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888-93.17. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevaci-zumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:2070-6.

Efficacy of Taxotere, Thalidomide,  and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer

http://doaj.org/search?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22term%22%3A%7B%22id%22%3A%22793ac9644a1345bcaa721cdf98fd24c2%22%7D%7D%5D%7D%7D%7D

Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals